Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of luxdegalutamide plus Pluvicto in PSMA-positive metastatic castration-resistant prostate cancer
MOH_2025-06-22_014137Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of luxdegalutamide and lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (3 arms), sponsored by Novartis. Started Jun 2025; status: active, not recruiting.
02
Drugs
luxdegalutamidelutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2025-06-22_014137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-22_014137.